Colorectal Cancer Clinical Trial
Official title:
The FLU-FOBT Program: Translation of an Evidence-Based Colorectal Cancer Screening Program to Primary Care Settings Where Disparities Persist
The investigators overall goals are to adapt, implement, evaluate, and disseminate the FLU-FOBT Program as an integrated nurse-run, primary care-based intervention that can reduce colorectal cancer screening disparities in resource-poor clinical settings. In this program, fecal occult blood tests (FOBT) are provided with influenza vaccinations (FLU) to eligible patients between the ages of 50 and 75 during FLU season. The investigators hypothesis is that the FLU-FOBT Program can be adapted for primary care settings and lead to higher rates of colorectal cancer screening (CRCS).
AIM 1 (Year 1): To adapt and pilot test the FLU-FOBT Program as a nurse-run intervention
during primary care visits at San Francisco's Chinatown Public Health Center. The FLU-FOBT
Program will be designed in such a way as to trigger the offering of fecal occult blood
testing (FOBT) to eligible patients whenever an influenza vaccination (FLU) is provided.
Specific components of the FLU-FOBT Program will be developed through a process of active
collaboration with health center staff. The FLU-FOBT Program will be implemented in the fall
of 2008-9 and evaluated with a combination of process measures in Year 1 of the study. This
formative work will be used to finalize the FLU-FOBT Program for further study of its
efficacy and robustness in other affiliated San Francisco public health centers.
AIM 2 (Year 2 and 3): To test the efficacy of the FLU-FOBT Program in improving colorectal
cancer screening rates in a time-randomized, controlled trial involving other public health
centers in the San Francisco Community Health Network that serve ethnically diverse,
economically disadvantaged patients. During the 2009-10 influenza vaccination season, the
FLU-FOBT Program will be tested in a randomized trial within 6 public health centers in San
Francisco. On half of randomly selected dates at each of these clinics, a nurse will follow
a protocol that directs them to offer FOBT to eligible patients whenever they are offered an
influenza vaccine (intervention), and on the other dates nurses will be directed to offer
just influenza vaccine alone (control). The primary efficacy outcome will be the proportion
of intervention subjects between the ages of 50 and 80 and are initially due for CRCS who
become up to date 3 months after the intervention is completed, as compared with similar
subjects in the control group.
AIM 3 (Years 2 and 3): To evaluate the robustness of the FLU-FOBT Program as implemented
within these 6 clinics. In the 2009-10 influenza vaccination season, we will also test the
robustness of the FLU-FOBT Program as implemented at the 6 sites that participate in the
time-randomized trial. Robustness will be measured according to the RE-AIM framework (Reach,
Effectiveness, Adoption, Implementation, and Maintenance) described by Glasgow and others
[2]. Reach will be measured as the proportion of the target population that is offered
screening, and Effectiveness will be measured as the proportion of the target population
that gets screened with the intervention. Adoption will be measured as the proportion of
invited influenza vaccination clinic sites and clinic staff members that participate;
Implementation will be assessed according to the fidelity with which participating sites and
clinic staff follow the key elements of FLU-FOBT Program protocol and how they adapt the
protocol to accommodate local needs and constraints. Maintenance will be assessed by
determining the number of intervention sites that continue the FLU-FOBT Program in the year
after the intervention has been completed, and the overall success of the program where it
is continued.
AIM 4 (Year 3): To develop a FLU-FOBT Program Toolkit that can be adopted locally and
disseminated to other public health clinics that rely on annual FOBT as a primary strategy
for average risk colorectal cancer screening. Study results from all participating health
centers will be used to develop an evidence-based FLU-FOBT Toolkit that can be distributed
and serve as a practical guide for clinical decision makers who wish to adapt and replicate
this intervention within clinics that serve diverse communities that experience disparities
in colorectal cancer screening. The Toolkit will include both key elements that must be
preserved in order for the FLU-FOBT Program to be successful, as well as examples of
enhancements successfully implemented in different clinics
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |